Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28,528 result(s) found for: Disease. Displaying page 1 of 1,427.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-004610-41 Sponsor Protocol Number: 205.368 Start Date*: 2007-05-28
    Sponsor Name:Boehringer Ingelheim España, S. A.
    Full Title: Ensayo aleatorizado, doble ciego, controlado con placebo de dos años de duración para evaluar cambios en la tolerancia al ejercicio en pacientes con EPOC tratados con Tiotropio (Spiriva® HandiHaler...
    Medical condition: Enfermedad Pulmonar Obstructiva Crónica (EPOC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) PT (Completed) IT (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001954-28 Sponsor Protocol Number: CQAB149B2334 Start Date*: 2006-10-10
    Sponsor Name:NovartisPharma Services AG
    Full Title: A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (300 & 600 µg o.d.)...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) DK (Completed) HU (Completed) GB (Completed) SK (Completed) DE (Completed) CZ (Completed) EE (Completed) LT (Completed) SE (Completed) LV (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002151-25 Sponsor Protocol Number: D4260C00007 Start Date*: 2008-07-03
    Sponsor Name:AstraZeneca AB
    Full Title: A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Multi-Centre Phase IIa Study to Assess the Effects on Biomarkers in Induced Sputum, Blood and Urine of AZD1236 Administered as Oral Ta...
    Medical condition: Chronic Obstructive Pulmonary Disease (study conducted in men or women, not of child bearing potential, aged 40 years or above).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-000025-29 Sponsor Protocol Number: CQAB149B2205 Start Date*: 2004-08-10
    Sponsor Name:Novartis Sweden AB
    Full Title: Full title of the trial : A randomized, double-blind, placebo-controlled, parallel group, multi-center, multiple dose (7 days) dose-ranging study, to assess the efficacy and safety of 4 doses of ...
    Medical condition: Moderate to severe Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    10010952
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004442-40 Sponsor Protocol Number: BY217/M2-114 Start Date*: 2005-03-21
    Sponsor Name:ALTANA Pharma AG
    Full Title: 500µg roflumilast once daily in combination with 50µg salmeterol twice daily versus 50µg salmeterol twice daily alone over 52 weeks in patients with COPD.
    Medical condition: COPD
    Disease: Version SOC Term Classification Code Term Level
    5.1 10010952 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004508-37 Sponsor Protocol Number: BY217/M2-128 Start Date*: 2007-01-08
    Sponsor Name:Nycomed GmbH
    Full Title: Effect of roflumilast in COPD patients treated with tiotropium. A 24-week, double-blind study with 500 µg roflumilast once daily versus placebo.
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) AT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-005080-28 Sponsor Protocol Number: BY217/M2-127 Start Date*: 2006-04-04
    Sponsor Name:ALTANA Pharma AG
    Full Title: Effect of roflumilast in COPD patients treated with salmeterol. A 24 week, double blind study with 500 mcg roflumilast once daily versus placebo
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010952 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021217-23 Sponsor Protocol Number: D3550C00002 Start Date*: 2010-10-22
    Sponsor Name:AstraZeneca AB
    Full Title: A 4 Week, Double Blind, Placebo Controlled, Randomised, Parallel Group, Multicentre, Phase IIa Study to Investigate the Safety and Tolerability of AZD5069 as Oral Capsules in Patients with Moderate...
    Medical condition: COPD
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-003655-36 Sponsor Protocol Number: CQVA149A2204 Start Date*: 2008-02-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, multicentre study to determine the effect of QVA149 on lung function in patients with Chronic Obstructive Pulmonary Disease (COPD)
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-010665-23 Sponsor Protocol Number: CQAB149B2350 Start Date*: 2009-07-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-week treatment, multi-center, randomized, parallel group, blinded, double dummy study to compare the efficacy and safety of Indacaterol (150 μg o.d.) delivered via a SDDPI with Tiotropium (18 ...
    Medical condition: COPD (chronic obstructive pulmonary disease)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) ES (Completed) AT (Completed) FR (Completed) HU (Completed) DK (Completed) PL (Completed) GB (Completed) SK (Completed) BE (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002563-23 Sponsor Protocol Number: CD-RI-MEDI8968-1103 Start Date*: 2012-03-15
    Sponsor Name:MedImmune Limited
    Full Title: A Phase 2 Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) LV (Completed) CZ (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-002166-38 Sponsor Protocol Number: 205.301 Start Date*: 2005-01-19
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A 12-week randomized, double blind, placebo controlled, parallel group trial evaluating the efficacy and safety of inhaled Tiotropium 18µg q.d. in patients with COPD and a concomitant diagnosis of ...
    Medical condition: Patients with COPD (chronic obstructive pulmonary disease) and a concomitant diagnosis of asthma (asthma bronchiale).
    Disease: Version SOC Term Classification Code Term Level
    7.0 10010952 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014418-86 Sponsor Protocol Number: 1222.40 Start Date*: 2010-01-05
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: Randomised, double-blind, double-dummy, placebo-controlled, 4-way cross-over study to characterise the 24-hour FEV1-time profiles of BI 1744 CL 5µg and 10µg (oral inhalation, delivered by the Respi...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013504-32 Sponsor Protocol Number: CNVA237A2304 Start Date*: 2009-10-20
    Sponsor Name:Novartis Farmaceutica, S.A.
    Full Title: Estudio aleatorizado, doble ciego, de grupos paralelos, controlado con placebo para valorar la eficacia, seguridad y tolerabilidad durante un tratamiento de 26 semanas con NVA237 en pacientes con ...
    Medical condition: Enfermedad Pulmonar Obstructiva Crónica (EPOC)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10010952 COPD LLT
    9 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-003634-15 Sponsor Protocol Number: CQAB149B2211 Start Date*: 2006-09-13
    Sponsor Name:NovartisPharma Services AG
    Full Title: An exploratory, double-blind comparison of inspiratory capacity (IC) and FEV1 in COPD patients following single dose administration of indacaterol and placebo and open-label b.i.d. administration o...
    Medical condition: Mild to severe COPD
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006305-16 Sponsor Protocol Number: CPJMR0052203 Start Date*: 2009-01-30
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open-label, multicenter, two-period crossover study to evaluate the 24 hour bronchodilator profile of Tiotropium Bromide Respimat® administered once daily versus twice daily in patien...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-010864-40 Sponsor Protocol Number: D1882C00003 Start Date*: 2009-06-18
    Sponsor Name:AstraZeneca AB
    Full Title: A double-blind, double-dummy, placebo-controlled, randomised, multi-centre, 5-way cross-over, single-dose study to investigate the local and systemic effects of inhaled AZD9164 compared to tiotropi...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-003184-31 Sponsor Protocol Number: Hx-CD20-408 Start Date*: 2007-05-31
    Sponsor Name:Genmab A/S
    Full Title: A double-blind, randomized, placebo-controlled, multi-center, Clinical Trial of ofatumumab, a fully human monoclonal anti-CD20 antibody in patients with moderate to severe stage Chronic Obstructive...
    Medical condition: Moderate to severe stage of Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005475-86 Sponsor Protocol Number: 7356 Start Date*: 2015-05-27
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Anti-platelet Therapy in the Primary Prevention of Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease.
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD) in patients who are considered to be at a higher risk of Coronary Artery Disease (CAD), myocardial infarction, and excess mortality.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004659-37 Sponsor Protocol Number: 1237.13 Start Date*: 2012-03-01
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (F...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009032 Chronic obstructive lung disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Apr 29 02:48:25 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA